CARB-X IS FUNDING GANGAGEN BIOTECHNOLOGIES TO DEVELOP A NEW DRUG TO TREAT PNEUMONIA CAUSED BY MULTIDRUG-RESISTANT KLEBSIELLA PNEUMONIAE BACTERIA
06 October 2020
CARB-X announced today it is awarding up to US$2.5 million to GangaGen Biotechnologies, headquartered in Bangalore, India, to develop novel antibacterial proteins, called klebicins, to treat pneumonia caused by Klebsiella pneumoniae, a difficult-to-treat bacteria belonging to the Enterobacterales family of Gram-negative pathogens. GangaGen will be eligible for an additional $8.1 million in funding from CARB-X if project milestones are met, subject to available funds.
Further reading: CARB-X
Author(s): Jennifer Robinson
Smart Innovations
OUR UNDERWRITERS
Unrestricted financial support by:
 |
Antimicrobial Resistance Fighter Coalition |
 |
Evotec |
 |
JSS University |
 |
INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS |
Technology Database
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.
